GAITHERSBURG, Md., April 24 /PRNewswire-FirstCall/ -- Digene Corporation today announced it intends to release fiscal 2006 third quarter results for the three months ended March 31, 2006 at the close of market on Monday, May 8, 2006.
Digene will host a conference call, which will be broadcast live over the Internet on Monday, May 8, 2006 at 4:30 p.m. EDT. The broadcast will be hosted on the Company’s website located at http://www.digene.com.
Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.
The online archive of the broadcast will be available within two hours of the live call and can be accessed through May 22, 2006, by dialing (800) 294-4341 or (203) 369-3229.
About Digene
Digene Corporation , based in Gaithersburg, MD, develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases -- with a focus on women’s cancers and infectious diseases. The company’s hc2 High-Risk HPV DNA Test(R) is the only test for human papillomavirus approved by the FDA, and is approved for both follow-up evaluation in women with inconclusive Pap results and for primary adjunctive screening with the Pap test in women age 30 and older. For primary adjunctive screening, it is marketed as both The Digene HPV Test and the DNAwithPap(R) Test. These brand names do not refer to the Digene product that tests for several types of the virus commonly referred to as “low-risk HPV,” which are not associated with cervical cancer. For more information, visit http://www.thehpvtest.com. Digene’s product portfolio also includes DNA tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses. For more information, visit the company’s Web site, http://www.digene.com. Investors also may contact Charles Fleischman at (301) 944-7000; journalists may contact Pam Rasmussen, (301) 944-7196. Digene(R), Hybrid Capture(R), hc2 High-Risk HPV DNA Test(R) and DNAwithPap(R) are registered trademarks of Digene Corporation.
Digene Corporation
CONTACT: Charles M. Fleischman, President, Digene Corporation,+1-301-944-7000; Investors, Jonathan Birt, Financial Dynamics,+1-212-850-5634; Media, Pam Rasmussen, Digene, +1-301-944-7196, or SeanLeous, Financial Dynamics, +1-212-850-5600
Web site: http://www.digene.com/
